Abstract
Hepatic encephalopathy (HE) is a common complication that occurs in 16–21% of end-stage cirrhosis patients. Emerging evidence suggests that systemic inflammation and oxidative stress may play a role in the development of HE. Recent understanding on the anti-inflammatory properties of human albumin has led to growing interest of using human albumin for the treatment and prevention of HE among decompensated patients. In this review, we aim to discuss the current evidence and controversies of using human albumin for the treatment and prevention of HE in advanced cirrhosis patients.
This is a preview of subscription content, log in via an institution to check access.
Data Availability
No original data from this manuscript.
References
Aldridge DR, Tranah EJ, Shawcross DL (2014) Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation. J Clin Exp Hepatol 5(Suppl 1):S7–S20. https://doi.org/10.1016/j.jceh.2014.06.004
Arora V, Vijayaraghavan R, Maiwall R, Sahney A, Ali R, Sarin SK (2020) Paracentesis-induced circulatory dysfunction with modest-volume paracentesis is partly ameliorated by albumin infusion in acute-on-chronic liver failure. Hepatology 72:1043–1055
Bajaj JS, Fagan A, Gavis EA, Kassam Z, Sikaroodi M, Gillevet PM (2019) Long-term Outcomes of Fecal Microbiota Transplantation in Patients With Cirrhosis. Gastroenterology 156(6):1921–1923e3. https://doi.org/10.1053/j.gastro.2019.01.033
Bañares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, RELIEF study group et al (2013) Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology 57(3):1153–1162. https://doi.org/10.1002/hep.26185
Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB et al (2010) Rifaximin treatment in hepatic encephalopathy. N Engl J Med 25(12):1071–1081. https://doi.org/10.1056/NEJMoa0907893
Bianchi G, Giovagnoli M, Sasdelli AS, Marchesini G (2012) Hepatic encephalopathy and health-related quality of life. Clin Liver Dis 16(1):159–170. https://doi.org/10.1016/j.cld.2011.12.003
Bohra A, Worland T, Hui S, Terbah R, Farrell A, Robertson M (2020) Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care. World J Gastroenterol 14;26(18):2221–2231. https://doi.org/10.3748/wjg.v26.i18.2221
Butterworth RF (2020) Beneficial effects of L-ornithine L-aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: a systematic review with meta-analysis. Metab Brain Dis 35(1):75–81. https://doi.org/10.1007/s11011-019-00463-8
Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, ANSWER Study Investigators et al (2018) Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet 16(10138):2417–2429. https://doi.org/10.1016/S0140-6736(18)30840-7
Chen TA, Tsao YC, Chen A, Lo GH, Lin CK, Yu HC et al (2009) Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis. Scand J Gastroenterol 44(5):619–625. https://doi.org/10.1080/00365520902719273
Di Pascoli M, Fasolato S, Piano S, Bolognesi M, Angeli P (2019) Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. Liver Int 39(1):98–105. https://doi.org/10.1111/liv.13968
Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT (2002) Hepatic encephalopathy–definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 35(3):716–721. https://doi.org/10.1053/jhep.2002.31250
Fernández J, Clària J, Amorós A, Aguilar F, Castro M, Casulleras M et al (2019) Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. Gastroenterology 157(1):149–162. https://doi.org/10.1053/j.gastro.2019.03.021
Garcia-Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R (2013) Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology 58(5):1836–1846. https://doi.org/10.1002/hep.26338
Ginés P, Arroyo V, Quintero E, Planas R, Bory F, Cabrera J et al (1987) Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 93(2):234–241. https://doi.org/10.1016/0016-5085(87)91007-9
Gluud LL, Vilstrup H, Morgan MY (2016) Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev 184:CD003044. https://doi.org/10.1002/14651858.CD003044.pub3
Görg B, Qvartskhava N, Bidmon HJ, Palomero-Gallagher N, Kircheis G, Zilles K et al (2010) Oxidative stress markers in the brain of patients with cirrhosis and hepatic encephalopathy. Hepatology 52(1):256–265. https://doi.org/10.1002/hep.23656
Jalan R, Kapoor D (2004) Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. Clin Sci (Lond) 106(5):467–474. https://doi.org/10.1042/CS20030357
Jayakumar AR, Norenberg MD (2018) Hyperammonemia in Hepatic Encephalopathy. J Clin Exp Hepatol 8(3):272–280. https://doi.org/10.1016/j.jceh.2018.06.007
Luo M, Guo JY, Cao WK (2015) Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis. World J Gastroenterol 21(41):11815–11824. https://doi.org/10.3748/wjg.v21.i41.11815
Mitzner SR (2011) Extracorporeal liver support-albumin dialysis with the Molecular Adsorbent Recirculating System (MARS). Ann Hepatol 10(Suppl 1):S21–S28
Montagnese S, Lauridsen M, Vilstrup H, Zarantonello L, Lakner G, Fitilev S et al (2021) A pilot study of golexanolone, a new GABA-A receptor-modulating steroid antagonist, in patients with covert hepatic encephalopathy. J Hepatol 75(1):98–107. https://doi.org/10.1016/j.jhep.2021.03.012
Planas R, Ginès P, Arroyo V, Llach J, Panés J, Vargas V et al (1990) Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology 99(6):1736–1744. https://doi.org/10.1016/0016-5085(90)90481-f
Patidar KR, Bajaj JS (2013) Antibiotics for the treatment of hepatic encephalopathy. Metab Brain Dis 28(2):307–312. https://doi.org/10.1007/s11011-013-9383-5
Riggio O, Nardelli S, Pasquale C, Pentassuglio I, Gioia S, Onori E et al (2016) No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Metab Brain Dis 31(6):1275–1281. https://doi.org/10.1007/s11011-015-9713-x
Sharma BC, Singh J, Srivastava S, Sangam A, Mantri AK, Trehanpati N et al (2017) Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy. J Gastroenterol Hepato 32(6):1234–1239. https://doi.org/10.1111/jgh.13666
Shawcross DL, Wright G, Olde Damink SW, Jalan R (2007) Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis 22(1):125–138. https://doi.org/10.1007/s11011-006-9042-1
Simón-Talero M, García-Martínez R, Torrens M, Augustin S, Gómez S, Pereira G et al (2013) Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J Hepatol 59(6):1184–1192. https://doi.org/10.1016/j.jhep.2013.07.020
Solà E, Solé C, Simón-Talero M, Martín-Llahí M, Castellote J, Garcia-Martínez R et al (2018) Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. J Hepatol 69(6):1250–1259. https://doi.org/10.1016/j.jhep.2018.08.006
Strauss E, Tramote R, Silva EP, Caly WR, Honain NZ, Maffei RA et al (1992) Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 39(6):542–545
Teh KB, Loo JH, Tam YC, Wong YJ (2021) Efficacy and safety of albumin infusion for overt hepatic encephalopathy: A systematic review and meta-analysis. Dig Liver Dis 53(7):817–823. https://doi.org/10.1016/j.dld.2021.04.030
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD et al (2014) Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 60(2):715–735. https://doi.org/10.1002/hep.27210
Funding
Dr Wong YJ is supported by the Nurturing Clinician Scientist Scheme (NCCS) award by SingHealth Duke-NUS Academic Medical Centre and National Medical Research Council Singapore.
Author information
Authors and Affiliations
Contributions
WYJ contributed to the study conception and design. Both authors contributed equally to the drafting and writing of the manuscript. Both authors reviewed and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
Both authors have no financial interests to be declared.
Ethics approval
No ethical approval is required for this review.
Informed consent
was not required as no human subjects were included in this short communication.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Wong, Y., Loo, J.H. Albumin therapy for hepatic encephalopathy: current evidence and controversies. Metab Brain Dis 38, 1759–1763 (2023). https://doi.org/10.1007/s11011-022-01002-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11011-022-01002-8